This is consistent with previous studies showing that genetic deletion of CB1R exacerbates striatal huntingtin aggregation in HD mouse models [6, 83], and that pharmacological activation of CB1R with Δ9-tetrahydrocannabinol (THC) alleviates mHtt accumulation [6]. The gene discussed is HTT; the disease is Huntington disease.